最近，SOX17 已成为非粘液性苗勒管癌（卵巢癌和子宫内膜癌）的一种有前景的生物标志物，与 PAX8 相比，其特异性有所提高，同时保持了相似的敏感性。然而，SOX17 在中肾样腺癌 (MLA) 中的表达仍有待探索，MLA 是一种女性生殖道癌，其组织发生不确定，但可能是苗勒氏管组织发生。本研究旨在解决这一差距。对来自子宫内膜或卵巢的 68 个 MLA、7 个宫颈中肾癌以及 6 个中肾残余/增生的全组织切片进行了 SOX17 免疫组织化学分析。使用基于染色分布和强度的四级评分系统，68% 的 MLA 显示阴性/低 (< 10%) SOX17 表达模式，这与大多数苗勒管癌中观察到的高表达形成对比。然而，22% 的 MLA 表现出高 SOX17 表达，与其他子宫内膜癌和卵巢癌类似。同样，7 例宫颈中肾癌中有 5 例 (72%) SOX17 阴性，但有 2 例 (28%) 呈阳性。所有中肾残余/增生均为 SOX17 阴性。大多数 MLA 呈阴性或表现出低 SOX17 表达，与其他类型苗勒管癌中常见的弥漫性强表达相反。然而，MLA 的一个子集表现出高 SOX17 表达。因此，当差异包括另一种非粘液性苗勒管癌时，SOX17 染色的缺失支持 MLA。 SOX17 也可能有助于区分中肾残余/增生与苗勒管恶性肿瘤和良性苗勒管腺病变。© 2024 John Wiley

Recently, SOX17 has emerged as a promising biomarker for non-mucinous Müllerian (ovarian and endometrial) carcinomas, demonstrating increased specificity in comparison to PAX8 while maintaining similar sensitivity. However, expression of SOX17 in mesonephric-like adenocarcinoma (MLA), a carcinoma of the female genital tract with uncertain, but probably Müllerian histogenesis, remains unexplored. This study aims to address this gap.SOX17 immunohistochemistry was performed on whole tissue sections from 68 MLAs originating from the endometrium or ovary and seven cervical mesonephric carcinomas, as well as six mesonephric remnants/hyperplasias. Using a four-tiered scoring system based on distribution and intensity of staining, 68% of MLA displayed a negative/low (< 10%) SOX17 expression pattern, which contrasts with the high expression observed in most Müllerian carcinomas. However, 22% of MLA demonstrated high SOX17 expression, similar to other endometrial and ovarian carcinomas. Similarly, five of seven (72%) mesonephric carcinomas of the cervix were SOX17-negative, but two cases (28%) were positive. All mesonephric remnants/hyperplasias were SOX17 negative.The majority of MLA are negative or exhibit low SOX17 expression, in contrast to the diffuse and strong expression commonly seen in other types of Müllerian carcinoma. However, a subset of MLAs demonstrate high SOX17 expression. Therefore, absence of SOX17 staining is supportive for MLA when the differential includes another non-mucinous Müllerian carcinoma. SOX17 may also be useful for differentiating mesonephric remnants/hyperplasias from Müllerian malignancies and benign Müllerian glandular lesions.© 2024 John Wiley & Sons Ltd.